It is estimated that 24 million Americans with chronic kidney disease are candidates for intensive blood pressure control under the new guidelines of Global Nonprofit Kidney Disease: Improving Global Outcomes.

The new recommendations change the systolic target to 120 mm Hg – from 130 mm Hg – and would affect about 69% of patients with chronic kidney disease in the United States, according to a follow-up study by Johns Hopkins University. That’s approximately seven million more people who could benefit from lowering blood pressure compared to the number below the previous systolic target.

“This is a major update to an influential set of guidelines for patients with chronic kidney disease and comes out against the backdrop of deteriorating blood pressure control in the United States,” said study leader Kathryn Foti, Ph.D.

At the time of the National Health and Nutrition Examination Survey 2015-18. In that year, 14 million American adults with chronic kidney disease did not take drugs to lower blood pressure, she noted.

“Blood pressure control is especially important for every seventh person in the United States who has chronic kidney disease,” said co-author and epidemiologist Dr. An intensive reduction to the new guidelines could have the added benefit of reducing cardiovascular disease among this group, he added.

The new guidelines and accompanying study were published Feb. 18 in the journal Kidney International.